<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>partneringNEWS</title>
	<atom:link href="http://ebdgroup.com/partneringnews/feed/" rel="self" type="application/rss+xml" />
	<link>http://ebdgroup.com/partneringnews</link>
	<description>for the biotech partnering community</description>
	<lastBuildDate>Mon, 15 Mar 2010 15:39:35 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.5</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Interview: Michael Yeomans, Bayer Schering Pharma</title>
		<link>http://ebdgroup.com/partneringnews/2010/03/interview-michael-yeomans-bayer-schering-pharma/</link>
		<comments>http://ebdgroup.com/partneringnews/2010/03/interview-michael-yeomans-bayer-schering-pharma/#comments</comments>
		<pubDate>Mon, 15 Mar 2010 15:39:35 +0000</pubDate>
		<dc:creator>ctheodoropulos</dc:creator>
				<category><![CDATA[Partnering People]]></category>

		<guid isPermaLink="false">http://ebdgroup.com/partneringnews/?p=1435</guid>
		<description><![CDATA[A featured speaker and panelist at conferences produced by EBD Group, Michael Yeomans consistently offers BIO-Europe Spring participants insights into industry trends and inspires discussions on future directions for dealmaking.
Dr Yeomans joined Bayer Schering Pharma in April 2007 as Senior Vice President, Head of Global Business Development &#38; Licensing, based in Berlin.  His arrival stirred <a href="http://ebdgroup.com/partneringnews/2010/03/interview-michael-yeomans-bayer-schering-pharma/" rel="bookmark" title="Permanent Link to Interview: Michael Yeomans, Bayer Schering Pharma"> Read more &#187;</a>

<h3>Related Posts</h3>
<ol>
		<li><a href="http://ebdgroup.com/partneringnews/2010/01/burgeoning-diagnostics-market-means-big-decisions-for-pharma/" rel="bookmark">Burgeoning diagnostics market means big decisions for pharma</a><!-- (11.907)--></li>
		<li><a href="http://ebdgroup.com/partneringnews/2009/08/pharma-will-use-its-cash-to-buy-while-biotech-is-cheap/" rel="bookmark">Pharma will use its cash to buy while biotech is cheap</a><!-- (11.6707)--></li>
		<li><a href="http://ebdgroup.com/partneringnews/2010/03/interview-montserrat-vendrell-ceo-biocat/" rel="bookmark">Interview: Montserrat Vendrell, CEO BioCat</a><!-- (9.52353)--></li>
	</ol>
]]></description>
		<wfw:commentRss>http://ebdgroup.com/partneringnews/2010/03/interview-michael-yeomans-bayer-schering-pharma/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Powerful growth of BIO-Europe Spring meets industry need for productive partnering</title>
		<link>http://ebdgroup.com/partneringnews/2010/03/bio-europe-spring-20-percent-year-on-year-growth-meeting-industry-need/</link>
		<comments>http://ebdgroup.com/partneringnews/2010/03/bio-europe-spring-20-percent-year-on-year-growth-meeting-industry-need/#comments</comments>
		<pubDate>Wed, 10 Mar 2010 08:58:34 +0000</pubDate>
		<dc:creator>jbrosky</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://ebdgroup.com/partneringnews/?p=1281</guid>
		<description><![CDATA[  
Gathering over 1,700 delegates from 1,061 companies in only its fourth year, BIO-Europe Spring 2010 provided proof of principle for conference producer EBD Group that “Partnering is here to stay in life sciences.&#8221;
This year offered a compelling demonstration that the introduction of BIO-Europe Spring in 2006 created the right event at the right <a href="http://ebdgroup.com/partneringnews/2010/03/bio-europe-spring-20-percent-year-on-year-growth-meeting-industry-need/" rel="bookmark" title="Permanent Link to Powerful growth of BIO-Europe Spring meets industry need for productive partnering"> Read more &#187;</a>

<h3>Related Posts</h3>
<ol>
		<li><a href="http://ebdgroup.com/partneringnews/2010/03/60-speakers-featured-at-bio-europe-spring-2010-march-8-10-in-barcelona/" rel="bookmark">60 speakers featured at BIO-Europe Spring 2010 March 8-10 in Barcelona</a><!-- (12.6037)--></li>
		<li><a href="http://ebdgroup.com/partneringnews/2010/03/blizzard-in-barcelona-snowbound-delegates-partner-through-the-storm-at-bio-europe-spring/" rel="bookmark">Blizzard in Barcelona: Snowbound delegates partner through the storm at BIO-Europe Spring<sup>&reg;</sup></a><!-- (11.561)--></li>
		<li><a href="http://ebdgroup.com/partneringnews/2009/11/12500-one-to-one-meetings-confirms-value-of-partnering-%e2%80%98in-good-times-and-bad%e2%80%99/" rel="bookmark">12,500 one-to-one meetings confirms value of partnering ‘in good times and bad’</a><!-- (10.1031)--></li>
	</ol>
]]></description>
		<wfw:commentRss>http://ebdgroup.com/partneringnews/2010/03/bio-europe-spring-20-percent-year-on-year-growth-meeting-industry-need/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A scent of Spring in dealmaking</title>
		<link>http://ebdgroup.com/partneringnews/2010/03/a-scent-of-spring-in-dealmaking/</link>
		<comments>http://ebdgroup.com/partneringnews/2010/03/a-scent-of-spring-in-dealmaking/#comments</comments>
		<pubDate>Wed, 10 Mar 2010 08:58:00 +0000</pubDate>
		<dc:creator>jbrosky</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://ebdgroup.com/partneringnews/?p=1217</guid>
		<description><![CDATA[Climbing out of the depressed conditions brought on by the great financial crisis of 2009, dealmaking regained some of its vigor during BIO-Europe Spring® 2010 in Barcelona. Confirming that the spring may indeed be back in biotech dealmaking, privately owned Cellzome and Glaxo used this high profile partnering venue to announce a drug discovery deal <a href="http://ebdgroup.com/partneringnews/2010/03/a-scent-of-spring-in-dealmaking/" rel="bookmark" title="Permanent Link to A scent of Spring in dealmaking"> Read more &#187;</a>

<h3>Related Posts</h3>
<ol>
		<li><a href="http://ebdgroup.com/partneringnews/2009/11/2010-dealmaking-forecast-partly-cloudy/" rel="bookmark">2010 Dealmaking forecast: Partly cloudy</a><!-- (12.1855)--></li>
		<li><a href="http://ebdgroup.com/partneringnews/2009/11/dealmaking-getting-more-creative/" rel="bookmark">Dealmaking getting more creative</a><!-- (10.1256)--></li>
		<li><a href="http://ebdgroup.com/partneringnews/2010/03/60-speakers-featured-at-bio-europe-spring-2010-march-8-10-in-barcelona/" rel="bookmark">60 speakers featured at BIO-Europe Spring 2010 March 8-10 in Barcelona</a><!-- (10.0971)--></li>
	</ol>
]]></description>
		<wfw:commentRss>http://ebdgroup.com/partneringnews/2010/03/a-scent-of-spring-in-dealmaking/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Blizzard in Barcelona: Snowbound delegates partner through the storm at BIO-Europe Spring&#174;</title>
		<link>http://ebdgroup.com/partneringnews/2010/03/blizzard-in-barcelona-snowbound-delegates-partner-through-the-storm-at-bio-europe-spring/</link>
		<comments>http://ebdgroup.com/partneringnews/2010/03/blizzard-in-barcelona-snowbound-delegates-partner-through-the-storm-at-bio-europe-spring/#comments</comments>
		<pubDate>Wed, 10 Mar 2010 08:57:26 +0000</pubDate>
		<dc:creator>jbrosky</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://ebdgroup.com/partneringnews/?p=1269</guid>
		<description><![CDATA[ 
Hoping to escape the long winter across many parts of Europe and North America, delegates arriving for BIO-Europe Spring 2010 in sunny Spain were greeted by a sudden winter storm that covered Barcelona under a blanket of snow.
Throughout the afternoon as the storm gathered force, delegates snapped photos with cell phones to record the <a href="http://ebdgroup.com/partneringnews/2010/03/blizzard-in-barcelona-snowbound-delegates-partner-through-the-storm-at-bio-europe-spring/" rel="bookmark" title="Permanent Link to Blizzard in Barcelona: Snowbound delegates partner through the storm at BIO-Europe Spring&#174;"> Read more &#187;</a>

<h3>Related Posts</h3>
<ol>
		<li><a href="http://ebdgroup.com/partneringnews/2010/03/60-speakers-featured-at-bio-europe-spring-2010-march-8-10-in-barcelona/" rel="bookmark">60 speakers featured at BIO-Europe Spring 2010 March 8-10 in Barcelona</a><!-- (20.4082)--></li>
		<li><a href="http://ebdgroup.com/partneringnews/2010/03/bio-europe-spring-20-percent-year-on-year-growth-meeting-industry-need/" rel="bookmark">Powerful growth of BIO-Europe Spring meets industry need for productive partnering</a><!-- (13.4312)--></li>
		<li><a href="http://ebdgroup.com/partneringnews/2009/10/shape-your-message-specifically-for-each-partner/" rel="bookmark">Workshop: Shape your message specifically for each partner</a><!-- (9.71954)--></li>
	</ol>
]]></description>
		<wfw:commentRss>http://ebdgroup.com/partneringnews/2010/03/blizzard-in-barcelona-snowbound-delegates-partner-through-the-storm-at-bio-europe-spring/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Alzheimer’s remains Holy Grail for drug development</title>
		<link>http://ebdgroup.com/partneringnews/2010/03/alzheimer%e2%80%99s-remains-holy-grail-for-drug-development/</link>
		<comments>http://ebdgroup.com/partneringnews/2010/03/alzheimer%e2%80%99s-remains-holy-grail-for-drug-development/#comments</comments>
		<pubDate>Wed, 10 Mar 2010 08:57:03 +0000</pubDate>
		<dc:creator>jbrosky</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://ebdgroup.com/partneringnews/?p=1233</guid>
		<description><![CDATA[If we learn from our failures, then Alzheimer’s disease presents the most exciting therapeutic area for drug discovery as it is a field littered with some of the most spectacular late stage wrecks in pharmacological research.
A complex disease, Alzheimer’s offers a range of targets that is surpassed only by the number of companies, universities, research <a href="http://ebdgroup.com/partneringnews/2010/03/alzheimer%e2%80%99s-remains-holy-grail-for-drug-development/" rel="bookmark" title="Permanent Link to Alzheimer’s remains Holy Grail for drug development"> Read more &#187;</a>

<h3>Related Posts</h3>
<ol>
		<li><a href="http://ebdgroup.com/partneringnews/2009/11/science-finally-delivering-break-throughs-in-oncology-drug-development/" rel="bookmark">Science finally delivering break-throughs in oncology drug development</a><!-- (20.7825)--></li>
		<li><a href="http://ebdgroup.com/partneringnews/2010/03/virtual-approach-gains-traction-as-alternate-path-to-corporate-development/" rel="bookmark">Virtual approach gains traction as alternate path to corporate development</a><!-- (10.876)--></li>
	</ol>
]]></description>
		<wfw:commentRss>http://ebdgroup.com/partneringnews/2010/03/alzheimer%e2%80%99s-remains-holy-grail-for-drug-development/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>China building trust in drive to innovate</title>
		<link>http://ebdgroup.com/partneringnews/2010/03/china-building-trust-in-drive-to-innovate/</link>
		<comments>http://ebdgroup.com/partneringnews/2010/03/china-building-trust-in-drive-to-innovate/#comments</comments>
		<pubDate>Wed, 10 Mar 2010 08:56:46 +0000</pubDate>
		<dc:creator>jbrosky</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://ebdgroup.com/partneringnews/?p=1212</guid>
		<description><![CDATA[Market opportunities in China are staggering, yet it was a question of trust that dominated the Q&#38;A period following the BIO-Europe Spring&#174; panel discussion “Why China Should be Factored into a Company’s Development and Commercialization Strategy.”
The central point of several members of the audience was to ask, “If I believe China can match quality standards <a href="http://ebdgroup.com/partneringnews/2010/03/china-building-trust-in-drive-to-innovate/" rel="bookmark" title="Permanent Link to China building trust in drive to innovate"> Read more &#187;</a>

<h3>Related Posts</h3>
<ol>
		<li><a href="http://ebdgroup.com/partneringnews/2009/10/piramal-healthcare-a-global-network-built-on-trust/" rel="bookmark">Piramal Healthcare: A global network built on trust</a><!-- (12.3443)--></li>
	</ol>
]]></description>
		<wfw:commentRss>http://ebdgroup.com/partneringnews/2010/03/china-building-trust-in-drive-to-innovate/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sharp focus is key to making the cut in niche and regional markets</title>
		<link>http://ebdgroup.com/partneringnews/2010/03/sharp-focus-is-key-to-making-the-cut-in-niche-and-regional-markets/</link>
		<comments>http://ebdgroup.com/partneringnews/2010/03/sharp-focus-is-key-to-making-the-cut-in-niche-and-regional-markets/#comments</comments>
		<pubDate>Wed, 10 Mar 2010 08:56:29 +0000</pubDate>
		<dc:creator>jbrosky</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://ebdgroup.com/partneringnews/?p=1221</guid>
		<description><![CDATA[Big pharma is searching for niche opportunities to tease out further growth, moving into the rare diseases and regional markets that are the hunting ground for midsize companies.
Leading a panel discussion asking “Can Mid-cap Companies Succeed with Targeted Regional Strategies?” moderator Jeff Conroy with Adjuvant Global Advisors set a context for competition highlighting the February <a href="http://ebdgroup.com/partneringnews/2010/03/sharp-focus-is-key-to-making-the-cut-in-niche-and-regional-markets/" rel="bookmark" title="Permanent Link to Sharp focus is key to making the cut in niche and regional markets"> Read more &#187;</a>

<h3>Related Posts</h3>
<ol>
		<li><a href="http://ebdgroup.com/partneringnews/2009/08/focus-efforts-and-move-quickly-to-proof-of-relevancy-milestone/" rel="bookmark">Focus efforts and move quickly to &#8216;proof of relevancy&#8217; milestone</a><!-- (12.4188)--></li>
	</ol>
]]></description>
		<wfw:commentRss>http://ebdgroup.com/partneringnews/2010/03/sharp-focus-is-key-to-making-the-cut-in-niche-and-regional-markets/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Virtual approach gains traction as alternate path to corporate development</title>
		<link>http://ebdgroup.com/partneringnews/2010/03/virtual-approach-gains-traction-as-alternate-path-to-corporate-development/</link>
		<comments>http://ebdgroup.com/partneringnews/2010/03/virtual-approach-gains-traction-as-alternate-path-to-corporate-development/#comments</comments>
		<pubDate>Wed, 10 Mar 2010 08:56:09 +0000</pubDate>
		<dc:creator>jbrosky</dc:creator>
				<category><![CDATA[News]]></category>

		<guid isPermaLink="false">http://ebdgroup.com/partneringnews/?p=1225</guid>
		<description><![CDATA[Venture capitalists have a well earned reputation for being hard nosed and matter of fact, so it was a rare opportunity to explore the leading edge of investment theory in a workshop session at BIO-Europe Spring® 2010 playfully titled, “The Virtues of Being Virtual.”
Organized  by the partners in Competitive Drug Development International, Grahaem Brown and <a href="http://ebdgroup.com/partneringnews/2010/03/virtual-approach-gains-traction-as-alternate-path-to-corporate-development/" rel="bookmark" title="Permanent Link to Virtual approach gains traction as alternate path to corporate development"> Read more &#187;</a>

<h3>Related Posts</h3>
<ol>
		<li><a href="http://ebdgroup.com/partneringnews/2010/03/alzheimer%e2%80%99s-remains-holy-grail-for-drug-development/" rel="bookmark">Alzheimer’s remains Holy Grail for drug development</a><!-- (10.7772)--></li>
		<li><a href="http://ebdgroup.com/partneringnews/2009/11/science-finally-delivering-break-throughs-in-oncology-drug-development/" rel="bookmark">Science finally delivering break-throughs in oncology drug development</a><!-- (9.60772)--></li>
	</ol>
]]></description>
		<wfw:commentRss>http://ebdgroup.com/partneringnews/2010/03/virtual-approach-gains-traction-as-alternate-path-to-corporate-development/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Interview: Montserrat Vendrell, CEO BioCat</title>
		<link>http://ebdgroup.com/partneringnews/2010/03/interview-montserrat-vendrell-ceo-biocat/</link>
		<comments>http://ebdgroup.com/partneringnews/2010/03/interview-montserrat-vendrell-ceo-biocat/#comments</comments>
		<pubDate>Thu, 04 Mar 2010 19:42:23 +0000</pubDate>
		<dc:creator>jbrosky</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Partnering People]]></category>

		<guid isPermaLink="false">http://ebdgroup.com/partneringnews/?p=1116</guid>
		<description><![CDATA[Spanish biotechnology is growing nearly 15 percent annually. Montserrat Vendrell says that is three times higher than German growth and five times higher than USA. Although the information is downplayed by countries, Spain is the country that has experienced the best biotechnological results in the last seven years.

<h3>Related Posts</h3>
<ol>
		<li><a href="http://ebdgroup.com/partneringnews/2010/03/interview-jaume-masana-esteve-phamaceuticals/" rel="bookmark">Interview: Jaume Masana, Esteve Phamaceuticals</a><!-- (11.3531)--></li>
		<li><a href="http://ebdgroup.com/partneringnews/2010/03/interview-michael-yeomans-bayer-schering-pharma/" rel="bookmark">Interview: Michael Yeomans, Bayer Schering Pharma</a><!-- (8.60775)--></li>
	</ol>
]]></description>
		<wfw:commentRss>http://ebdgroup.com/partneringnews/2010/03/interview-montserrat-vendrell-ceo-biocat/feed/</wfw:commentRss>
		<slash:comments>3</slash:comments>
		</item>
		<item>
		<title>Interview: Jaume Masana, Esteve Phamaceuticals</title>
		<link>http://ebdgroup.com/partneringnews/2010/03/interview-jaume-masana-esteve-phamaceuticals/</link>
		<comments>http://ebdgroup.com/partneringnews/2010/03/interview-jaume-masana-esteve-phamaceuticals/#comments</comments>
		<pubDate>Thu, 04 Mar 2010 14:43:03 +0000</pubDate>
		<dc:creator>jbrosky</dc:creator>
				<category><![CDATA[News]]></category>
		<category><![CDATA[Partnering People]]></category>

		<guid isPermaLink="false">http://ebdgroup.com/partneringnews/?p=1032</guid>
		<description><![CDATA[In an exclusive interview with partneringNEWS, Dr Masana sets out the strategic directions for Esteve through to 2015 and describes the qualities the company seeks in new programs.

<h3>Related Posts</h3>
<ol>
		<li><a href="http://ebdgroup.com/partneringnews/2010/03/interview-montserrat-vendrell-ceo-biocat/" rel="bookmark">Interview: Montserrat Vendrell, CEO BioCat</a><!-- (10.2162)--></li>
		<li><a href="http://ebdgroup.com/partneringnews/2010/03/interview-michael-yeomans-bayer-schering-pharma/" rel="bookmark">Interview: Michael Yeomans, Bayer Schering Pharma</a><!-- (9.27315)--></li>
	</ol>
]]></description>
		<wfw:commentRss>http://ebdgroup.com/partneringnews/2010/03/interview-jaume-masana-esteve-phamaceuticals/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
	</channel>
</rss>
